Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review
- 2 November 2021
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 37 (11) , 1855-1858
Abstract
Introduction Bradykinin-mediated angioedema is a rare but potentially fatal adverse event. Angioedema induced by angiotensin-converting enzyme (ACE) inhibitors is generally attributed to an inhibition of bradykinin degradation following ACE inhibition. Clinical studies on ACE inhibitors mainly focus on their efficacy. Few examine their potential to generate undesirable adverse effects, particularly with regard to angioedema. Case description We report here a case of angioedema occurring after ramipril initiation in a patient chronically treated with quinapril. Angioedema subsided spontaneously after ramipril discontinuation and quinapril reintroduction. Discussion and conclusions Our clinical case suggests that despite similar pharmacodynamic properties, quinapril and ramipril do not have the same potential to generate angioedema. To explain this difference, we suggest a potentiation of the effect of bradykinin at the B2 receptor level by ramipril, which does not occur with quinapril. Consequently, angioedema may not always be a class effect of ACE inhibitors.Keywords
This publication has 22 references indexed in Scilit:
- Angioedema induced by angiotensin converting enzyme inhibitors, potentiated by m-TOR inhibitors: successful treatment with icatibantIntensive Care Medicine, 2014
- Not All Angiotensin-Converting Enzyme Inhibitors Are Equal: Focus on Ramipril and PerindoprilPostgraduate Medicine, 2013
- Current pharmacotherapy of bradykinin-mediated angioedemaExpert Opinion on Pharmacotherapy, 2013
- Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Renin–Angiotensin System InhibitorsThe American Journal of Cardiology, 2012
- The Spectrum and Treatment of AngioedemaThe American Journal of Medicine, 2008
- Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACEEuropean Journal of Pharmacology, 2007
- ACE inhibitor potentiation of bradykinin‐induced venoconstrictionBritish Journal of Pharmacology, 1997
- Clinical Pharmacokinetics of RamiprilClinical Pharmacokinetics, 1994
- Comparative pharmacokinetics of captopril, enalapril, and quinaprilThe American Journal of Cardiology, 1992
- Inhibition of Angiotensin-Converting Enzyme (ACE) in Plasma and TissueJournal of Cardiovascular Pharmacology, 1990